About
Mats Ohlin is a Professor at the Department of Immunotechnology, Faculty of Engineering, Lund University. His research focuses on human antibody technology, antigen-designed libraries, and molecular engineering of carbohydrate-binding scaffolds, with applications in immunology, virology, and allergy. He leads the Lund branch of Science for Life Laboratory's Human Antibody Therapeutics National Facility, supporting academic drug discovery in Sweden.
Research Interests:
- Human antibody responses in health and disease
- Phage display technology for molecular evolution
- Cytomegalovirus-specific antibody repertoires
- Human IgE in allergy (anti-allergome resource 4BUH)
- Carbohydrate-binding protein design
Leadership Roles:
- Head of Department of Immunotechnology (2018-2024)
- Dept. Director of 3rd Cycle Studies (since 2025)
- Dept. Director of LU-ATMP (since 2023)
Awards:
- Excellent Teaching Practitioner (2008)
Entrepreneurship: Co-founder of Immunovia AB (2007), a company focused on biomarker discovery for cancer diagnostics.
0Publications listed
